S167: PREDICTION OF RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION USING INDIVIDUALIZED MEASURABLE RESIDUAL DISEASE MARKERS; THE PROSPECTIVE NORDIC STUDY NMDSG14B
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000843560.87168.a9 |
| _version_ | 1797287887837855744 |
|---|---|
| author | M. Tobiasson T. Pandzic J. Illman L. Nilsson S. Weström K. Sollander E. Ejerblad A. Olsnes Kittang G. Olesen O. Werlenius A. Björklund J. Wiggh C. lindholm F. Lorentz B. Rasmussen J. Cammenga D. Weber D. Grönnås M. Dimitriou S. Kytölä G. Walldin P. Ljungman K. Groenbeck S. Mielke S. E. Jacobsen F. Ebeling L. Cavelier L. Smidstrup Friis I. Dybedal E. Hellström-Lindberg |
| author_facet | M. Tobiasson T. Pandzic J. Illman L. Nilsson S. Weström K. Sollander E. Ejerblad A. Olsnes Kittang G. Olesen O. Werlenius A. Björklund J. Wiggh C. lindholm F. Lorentz B. Rasmussen J. Cammenga D. Weber D. Grönnås M. Dimitriou S. Kytölä G. Walldin P. Ljungman K. Groenbeck S. Mielke S. E. Jacobsen F. Ebeling L. Cavelier L. Smidstrup Friis I. Dybedal E. Hellström-Lindberg |
| author_sort | M. Tobiasson |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:41:20Z |
| format | Article |
| id | doaj.art-366b789350174058af56c71fc57e3c9b |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:41:20Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-366b789350174058af56c71fc57e3c9b2024-03-02T03:51:39ZengWileyHemaSphere2572-92412022-06-016686910.1097/01.HS9.0000843560.87168.a9202206003-00068S167: PREDICTION OF RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION USING INDIVIDUALIZED MEASURABLE RESIDUAL DISEASE MARKERS; THE PROSPECTIVE NORDIC STUDY NMDSG14BM. Tobiasson0T. Pandzic1J. Illman2L. Nilsson3S. Weström4K. Sollander5E. Ejerblad6A. Olsnes Kittang7G. Olesen8O. Werlenius9A. Björklund10J. Wiggh11C. lindholm12F. Lorentz13B. Rasmussen14J. Cammenga15D. Weber16D. Grönnås17M. Dimitriou18S. Kytölä19G. Walldin20P. Ljungman21K. Groenbeck22S. Mielke23S. E. Jacobsen24F. Ebeling25L. Cavelier26L. Smidstrup Friis27I. Dybedal28E. Hellström-Lindberg291 Hematology, Karolinska University Hospital, Stockholm2 Department of Immunology, Genetics and Pathology, Science for life, Uppsala, Sweden3 Hematology, Helsinki University Hospital, Helsinki, Finland4 Hematology, Lund University Hospital, Lund2 Department of Immunology, Genetics and Pathology, Science for life, Uppsala, Sweden2 Department of Immunology, Genetics and Pathology, Science for life, Uppsala, Sweden5 Hematology, Akademiska sjukhuset, Uppsala, Sweden6 Hematology, Haukeland University Hospital, Bergen, Norway7 Hematology, Arhus University Hospital, Århus, Denmark8 Hematology, Sahlgrenska University Hospital, Gothenburg9 Centre for allogeneic stem cell transplantation, Karolinska University Hospital, Stockholm1 Hematology, Karolinska University Hospital, Stockholm1 Hematology, Karolinska University Hospital, Stockholm10 Hematology, Norrlands University Hospital, Umeå11 Hematology, Örebro University Hospital, Örebro12 Hematology, Universitetssjukhuset, Linköping, Sweden13 Hematology, Odense University Hospital, Odense, Denmark14 Institution for environmental medicine15 Centre for hematology and regenerative medicine, Institution for medicine, Huddinge, Karolinska Institute, Stockholm, Sweden16 HUS Diagnostic Center, HUSLAB, Helsinki University Hospital, Helsinki, Finland15 Centre for hematology and regenerative medicine, Institution for medicine, Huddinge, Karolinska Institute, Stockholm, Sweden9 Centre for allogeneic stem cell transplantation, Karolinska University Hospital, Stockholm17 Hematology, Rigshospitalet, Copenhagen, Denmark9 Centre for allogeneic stem cell transplantation, Karolinska University Hospital, Stockholm15 Centre for hematology and regenerative medicine, Institution for medicine, Huddinge, Karolinska Institute, Stockholm, Sweden3 Hematology, Helsinki University Hospital, Helsinki, Finland2 Department of Immunology, Genetics and Pathology, Science for life, Uppsala, Sweden17 Hematology, Rigshospitalet, Copenhagen, Denmark18 Hematology, Oslo University Hospital, Oslo, Norway1 Hematology, Karolinska University Hospital, Stockholmhttp://journals.lww.com/10.1097/01.HS9.0000843560.87168.a9 |
| spellingShingle | M. Tobiasson T. Pandzic J. Illman L. Nilsson S. Weström K. Sollander E. Ejerblad A. Olsnes Kittang G. Olesen O. Werlenius A. Björklund J. Wiggh C. lindholm F. Lorentz B. Rasmussen J. Cammenga D. Weber D. Grönnås M. Dimitriou S. Kytölä G. Walldin P. Ljungman K. Groenbeck S. Mielke S. E. Jacobsen F. Ebeling L. Cavelier L. Smidstrup Friis I. Dybedal E. Hellström-Lindberg S167: PREDICTION OF RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION USING INDIVIDUALIZED MEASURABLE RESIDUAL DISEASE MARKERS; THE PROSPECTIVE NORDIC STUDY NMDSG14B HemaSphere |
| title | S167: PREDICTION OF RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION USING INDIVIDUALIZED MEASURABLE RESIDUAL DISEASE MARKERS; THE PROSPECTIVE NORDIC STUDY NMDSG14B |
| title_full | S167: PREDICTION OF RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION USING INDIVIDUALIZED MEASURABLE RESIDUAL DISEASE MARKERS; THE PROSPECTIVE NORDIC STUDY NMDSG14B |
| title_fullStr | S167: PREDICTION OF RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION USING INDIVIDUALIZED MEASURABLE RESIDUAL DISEASE MARKERS; THE PROSPECTIVE NORDIC STUDY NMDSG14B |
| title_full_unstemmed | S167: PREDICTION OF RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION USING INDIVIDUALIZED MEASURABLE RESIDUAL DISEASE MARKERS; THE PROSPECTIVE NORDIC STUDY NMDSG14B |
| title_short | S167: PREDICTION OF RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION USING INDIVIDUALIZED MEASURABLE RESIDUAL DISEASE MARKERS; THE PROSPECTIVE NORDIC STUDY NMDSG14B |
| title_sort | s167 prediction of relapse after allogeneic stem cell transplantation using individualized measurable residual disease markers the prospective nordic study nmdsg14b |
| url | http://journals.lww.com/10.1097/01.HS9.0000843560.87168.a9 |
| work_keys_str_mv | AT mtobiasson s167predictionofrelapseafterallogeneicstemcelltransplantationusingindividualizedmeasurableresidualdiseasemarkerstheprospectivenordicstudynmdsg14b AT tpandzic s167predictionofrelapseafterallogeneicstemcelltransplantationusingindividualizedmeasurableresidualdiseasemarkerstheprospectivenordicstudynmdsg14b AT jillman s167predictionofrelapseafterallogeneicstemcelltransplantationusingindividualizedmeasurableresidualdiseasemarkerstheprospectivenordicstudynmdsg14b AT lnilsson s167predictionofrelapseafterallogeneicstemcelltransplantationusingindividualizedmeasurableresidualdiseasemarkerstheprospectivenordicstudynmdsg14b AT swestrom s167predictionofrelapseafterallogeneicstemcelltransplantationusingindividualizedmeasurableresidualdiseasemarkerstheprospectivenordicstudynmdsg14b AT ksollander s167predictionofrelapseafterallogeneicstemcelltransplantationusingindividualizedmeasurableresidualdiseasemarkerstheprospectivenordicstudynmdsg14b AT eejerblad s167predictionofrelapseafterallogeneicstemcelltransplantationusingindividualizedmeasurableresidualdiseasemarkerstheprospectivenordicstudynmdsg14b AT aolsneskittang s167predictionofrelapseafterallogeneicstemcelltransplantationusingindividualizedmeasurableresidualdiseasemarkerstheprospectivenordicstudynmdsg14b AT golesen s167predictionofrelapseafterallogeneicstemcelltransplantationusingindividualizedmeasurableresidualdiseasemarkerstheprospectivenordicstudynmdsg14b AT owerlenius s167predictionofrelapseafterallogeneicstemcelltransplantationusingindividualizedmeasurableresidualdiseasemarkerstheprospectivenordicstudynmdsg14b AT abjorklund s167predictionofrelapseafterallogeneicstemcelltransplantationusingindividualizedmeasurableresidualdiseasemarkerstheprospectivenordicstudynmdsg14b AT jwiggh s167predictionofrelapseafterallogeneicstemcelltransplantationusingindividualizedmeasurableresidualdiseasemarkerstheprospectivenordicstudynmdsg14b AT clindholm s167predictionofrelapseafterallogeneicstemcelltransplantationusingindividualizedmeasurableresidualdiseasemarkerstheprospectivenordicstudynmdsg14b AT florentz s167predictionofrelapseafterallogeneicstemcelltransplantationusingindividualizedmeasurableresidualdiseasemarkerstheprospectivenordicstudynmdsg14b AT brasmussen s167predictionofrelapseafterallogeneicstemcelltransplantationusingindividualizedmeasurableresidualdiseasemarkerstheprospectivenordicstudynmdsg14b AT jcammenga s167predictionofrelapseafterallogeneicstemcelltransplantationusingindividualizedmeasurableresidualdiseasemarkerstheprospectivenordicstudynmdsg14b AT dweber s167predictionofrelapseafterallogeneicstemcelltransplantationusingindividualizedmeasurableresidualdiseasemarkerstheprospectivenordicstudynmdsg14b AT dgronnas s167predictionofrelapseafterallogeneicstemcelltransplantationusingindividualizedmeasurableresidualdiseasemarkerstheprospectivenordicstudynmdsg14b AT mdimitriou s167predictionofrelapseafterallogeneicstemcelltransplantationusingindividualizedmeasurableresidualdiseasemarkerstheprospectivenordicstudynmdsg14b AT skytola s167predictionofrelapseafterallogeneicstemcelltransplantationusingindividualizedmeasurableresidualdiseasemarkerstheprospectivenordicstudynmdsg14b AT gwalldin s167predictionofrelapseafterallogeneicstemcelltransplantationusingindividualizedmeasurableresidualdiseasemarkerstheprospectivenordicstudynmdsg14b AT pljungman s167predictionofrelapseafterallogeneicstemcelltransplantationusingindividualizedmeasurableresidualdiseasemarkerstheprospectivenordicstudynmdsg14b AT kgroenbeck s167predictionofrelapseafterallogeneicstemcelltransplantationusingindividualizedmeasurableresidualdiseasemarkerstheprospectivenordicstudynmdsg14b AT smielke s167predictionofrelapseafterallogeneicstemcelltransplantationusingindividualizedmeasurableresidualdiseasemarkerstheprospectivenordicstudynmdsg14b AT sejacobsen s167predictionofrelapseafterallogeneicstemcelltransplantationusingindividualizedmeasurableresidualdiseasemarkerstheprospectivenordicstudynmdsg14b AT febeling s167predictionofrelapseafterallogeneicstemcelltransplantationusingindividualizedmeasurableresidualdiseasemarkerstheprospectivenordicstudynmdsg14b AT lcavelier s167predictionofrelapseafterallogeneicstemcelltransplantationusingindividualizedmeasurableresidualdiseasemarkerstheprospectivenordicstudynmdsg14b AT lsmidstrupfriis s167predictionofrelapseafterallogeneicstemcelltransplantationusingindividualizedmeasurableresidualdiseasemarkerstheprospectivenordicstudynmdsg14b AT idybedal s167predictionofrelapseafterallogeneicstemcelltransplantationusingindividualizedmeasurableresidualdiseasemarkerstheprospectivenordicstudynmdsg14b AT ehellstromlindberg s167predictionofrelapseafterallogeneicstemcelltransplantationusingindividualizedmeasurableresidualdiseasemarkerstheprospectivenordicstudynmdsg14b |